Xenon Pharmaceuticals Stock Performance

XENE Stock  USD 41.48  0.14  0.34%   
Xenon Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm maintains a market beta of 0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xenon Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xenon Pharmaceuticals is expected to be smaller as well. Xenon Pharmaceuticals right now maintains a risk of 2.04%. Please check out Xenon Pharmaceuticals semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Xenon Pharmaceuticals will be following its historical returns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Xenon Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, Xenon Pharmaceuticals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more

Actual Historical Performance (%)

One Day Return
(0.34)
Year To Date Return
(6.77)
Ten Year Return
505.55
All Time Return
295.05
1
Disposition of 14375 shares by Mortimer Ian of Xenon Pharmaceuticals at 45.03 subject to Rule 16b-3
12/05/2025
2
The top 5 stock picks for biotech in 2026 William Blair - Fierce Biotech
12/23/2025
3
Xenon Pharmaceuticals Trading 3.8 percent Higher - Heres Why - MarketBeat
12/31/2025
4
Disposition of 40000 shares by Mortimer Ian of Xenon Pharmaceuticals at 7.49 subject to Rule 16b-3
01/02/2026
5
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
01/05/2026
6
Acquisition by Mortimer Ian of 65000 shares of Xenon Pharmaceuticals subject to Rule 16b-3
01/09/2026
7
Xenon Outlines Key Upcoming Milestones at the 2026J.P. Morgan Healthcare Conference
01/12/2026
8
Did Xenons Azetukalner NDA Timeline and Neuropsychiatric Pivot Just Reframe Xenon Pharmaceuticals Investment Narrative
01/16/2026
9
Xenon Pharmaceuticals Inc. Receives 54.82 Average Target Price from Analysts
01/29/2026
10
Stifel raises Xenon Pharmaceuticals stock price target to 66 on XEN1101 potential - Investing.com India
02/09/2026
Begin Period Cash Flow148.6 M
Total Cashflows From Investing Activities165 M

Xenon Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  4,061  in Xenon Pharmaceuticals on November 17, 2025 and sell it today you would earn a total of  87.00  from holding Xenon Pharmaceuticals or generate 2.14% return on investment over 90 days. Xenon Pharmaceuticals is currently generating 0.0546% in daily expected returns and assumes 2.0387% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Xenon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Xenon Pharmaceuticals is expected to generate 1.84 times less return on investment than the market. In addition to that, the company is 2.67 times more volatile than its market benchmark. It trades about 0.03 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of volatility.

Xenon Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of Xenon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 41.48 90 days 41.48 
about 70.5
Based on a normal probability distribution, the odds of Xenon Pharmaceuticals to move above the current price in 90 days from now is about 70.5 (This Xenon Pharmaceuticals probability density function shows the probability of Xenon Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Xenon Pharmaceuticals has a beta of 0.41. This entails as returns on the market go up, Xenon Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Xenon Pharmaceuticals will be expected to be much smaller as well. Additionally Xenon Pharmaceuticals has an alpha of 0.1029, implying that it can generate a 0.1 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Xenon Pharmaceuticals Price Density   
       Price  

Predictive Modules for Xenon Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Xenon Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
39.3241.3643.40
Details
Intrinsic
Valuation
LowRealHigh
37.3349.0251.06
Details
19 Analysts
Consensus
LowTargetHigh
50.8055.8261.96
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.33-1.15-0.54
Details

Xenon Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Xenon Pharmaceuticals is not an exception. The market had few large corrections towards the Xenon Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Xenon Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Xenon Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.10
β
Beta against Dow Jones0.41
σ
Overall volatility
1.67
Ir
Information ratio 0.03

Xenon Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Xenon Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Xenon Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Net Loss for the year was (234.33 M) with loss before overhead, payroll, taxes, and interest of (265.21 M).
Xenon Pharmaceuticals currently holds about 788.24 M in cash with (181.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66.
Xenon Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company outstanding shares are owned by institutional investors
Latest headline from news.google.com: Stifel raises Xenon Pharmaceuticals stock price target to 66 on XEN1101 potential - Investing.com India

Xenon Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Xenon Stock often depends not only on the future outlook of the current and potential Xenon Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Xenon Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding77.9 M
Cash And Short Term Investments626.9 M

Xenon Pharmaceuticals Fundamentals Growth

Xenon Stock prices reflect investors' perceptions of the future prospects and financial health of Xenon Pharmaceuticals, and Xenon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xenon Stock performance.

About Xenon Pharmaceuticals Performance

By analyzing Xenon Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Xenon Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xenon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xenon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.34)(0.35)
Return On Capital Employed(0.42)(0.44)
Return On Assets(0.34)(0.35)
Return On Equity(0.36)(0.37)

Things to note about Xenon Pharmaceuticals performance evaluation

Checking the ongoing alerts about Xenon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xenon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Net Loss for the year was (234.33 M) with loss before overhead, payroll, taxes, and interest of (265.21 M).
Xenon Pharmaceuticals currently holds about 788.24 M in cash with (181.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66.
Xenon Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company outstanding shares are owned by institutional investors
Latest headline from news.google.com: Stifel raises Xenon Pharmaceuticals stock price target to 66 on XEN1101 potential - Investing.com India
Evaluating Xenon Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Xenon Pharmaceuticals' stock performance include:
  • Analyzing Xenon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xenon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Xenon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Xenon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xenon Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Xenon Pharmaceuticals' stock. These opinions can provide insight into Xenon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Xenon Pharmaceuticals' stock performance is not an exact science, and many factors can impact Xenon Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Xenon Stock analysis

When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Global Correlations
Find global opportunities by holding instruments from different markets